IFNA1 and HIV-1 infection: Thus, subtype specific IFNα treatment of HIV-1 infection remains a viable therapeutic option and is worth pursuing, as evidenced by continued HIV-1 clinical trials aiming to harness the potent effects of IFNα on the HIV-1 reservoir.